Next Article in Journal
Leptin’s Pro-Angiogenic Signature in Breast Cancer
Next Article in Special Issue
Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
Previous Article in Journal / Special Issue
Emerging Biomarkers in Glioblastoma
Cancers 2013, 5(3), 1120-1139; doi:10.3390/cancers5031120
Review

Is Glioblastoma an Epigenetic Malignancy?

 and *
Received: 15 July 2013; in revised form: 13 August 2013 / Accepted: 19 August 2013 / Published: 3 September 2013
(This article belongs to the Special Issue Glioblastoma)
View Full-Text   |   Download PDF [544 KB, uploaded 3 September 2013]   |   Browse Figure
Abstract: Epigenetic modifications control gene expression by regulating the access of nuclear proteins to their target DNA and have been implicated in both normal cell differentiation and oncogenic transformation. Epigenetic abnormalities can occur both as a cause and as a consequence of cancer. Oncogenic transformation can deeply alter the epigenetic information enclosed in the pattern of DNA methylation or histone modifications. In addition, in some cancers epigenetic dysfunctions can drive oncogenic transformation. Growing evidence emphasizes the interplay between metabolic disturbances, epigenomic changes and cancer, i.e., mutations in the metabolic enzymes SDH, FH, and IDH may contribute to cancer development. Epigenetic-based mechanisms are reversible and the possibility of “resetting” the abnormal cancer epigenome by applying pharmacological or genetic strategies is an attractive, novel approach. Gliomas are incurable with all current therapeutic approaches and new strategies are urgently needed. Increasing evidence suggests the role of epigenetic events in development and/or progression of gliomas. In this review, we summarize current data on the occurrence and significance of mutations in the epigenetic and metabolic enzymes in pathobiology of gliomas. We discuss emerging therapies targeting specific epigenetic modifications or chromatin modifying enzymes either alone or in combination with other treatment regimens.
Keywords: epigenetics; methylator phenotype; histone modifying enzymes; inhibitors and glioblastoma epigenetics; methylator phenotype; histone modifying enzymes; inhibitors and glioblastoma
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Maleszewska, M.; Kaminska, B. Is Glioblastoma an Epigenetic Malignancy? Cancers 2013, 5, 1120-1139.

AMA Style

Maleszewska M, Kaminska B. Is Glioblastoma an Epigenetic Malignancy? Cancers. 2013; 5(3):1120-1139.

Chicago/Turabian Style

Maleszewska, Marta; Kaminska, Bozena. 2013. "Is Glioblastoma an Epigenetic Malignancy?" Cancers 5, no. 3: 1120-1139.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert